Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Individualized therapy in non-small-cell lung cancer: future versus current clinical practice

Oncogene volume 28, pages S38–S45 (2009)Cite this article

Abstract

Despite advances in the management of non-small-cell lung cancer (NSCLC), including the introduction of targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors, improvements in survival are marginal and the overall prognosis for patients remains poor. Tailoring therapy to the individual patient is a promising approach for selecting the most appropriate therapeutic regimens to maximize efficacy and minimize toxicity. The identification of predictive biomarkers that can guide treatment decisions is an important step for individualized therapy and in ultimately improving patient outcomes. Genomic and proteomic studies provide a means for the molecular profiling of tumor tissue from patients with NSCLC, and allow tailoring of therapy whereby the most appropriate treatment is administered to each individual patient. Although there are still significant challenges to implementing genomic and proteomic testing in clinical practice, the rapid development of newer technologies provides hope for overcoming these barriers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  • Aebersold R, Mann M . (2003). Mass spectrometry-based proteomics. Nature 422: 198–207.

    Article  CAS  Google Scholar 

  • Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM et al. (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25–29.

    Article  CAS  Google Scholar 

  • Atkins D, Reiffen K, Tegtmeier C, Winther H, Bonato MS, Störkel S . (2004). Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52: 893–901.

    Article  CAS  Google Scholar 

  • Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE et al. (2002). Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816–824.

    Article  CAS  Google Scholar 

  • Bonomi PD, Buckingham L, Coon J . (2007). Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 13 (15 Suppl): 4606s–44612s.

    Article  CAS  Google Scholar 

  • Chen G, Gharib TG, Wang H, Huang CC, Kuick R, Thomas DG et al. (2003). Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci USA 100: 13537–13542.

    Article  CAS  Google Scholar 

  • Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H et al. (2005). Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology 68: 382–390.

    Article  CAS  Google Scholar 

  • Clark GM, Cameron T, Das Gupta A . (2006). Clinical benefit of erlotinib in male smokers with squamous-cell NSCLC. Proc Am Soc Clin Oncol 24 (18 Suppl): 7166.

    Google Scholar 

  • Conrad DH, Goyette J, Thomas PS . (2008). Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 23: 78–84.

    Article  Google Scholar 

  • Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A et al. (2005). Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16: 1081–1086.

    Article  CAS  Google Scholar 

  • de Reynies A, Boige V, Milano G, Faivre J, Laurent-Puig P . (2008). KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol 26: 2228–2230.

    Article  Google Scholar 

  • De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N et al. (2008). KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508–515.

    Article  CAS  Google Scholar 

  • Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP et al. (2007). Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166–1169.

    Article  CAS  Google Scholar 

  • Douillard JY, Hirsh V, Mok TS, Socinski MA, Watkins C, Lowe E et al. (2008). Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 26 (Suppl): 424s, abstract 8001.

    Article  Google Scholar 

  • Dowlati A, Gray R, Johnson DH, Schiller JH, Brahmer J, Sandler AB et al. (2006). Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel +/− bevacizumab in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 24: 370s; abstract 7027.

    Article  Google Scholar 

  • Dziadziuszko R, Hirsch FR, Varella-Garcia M, Thatcher N, Mann H, Watkins C et al. (2007). Epidermal growth factor receptor (EGFR) immunohistochemistry: comparison of antibodies (Abs) and cut points to predict benefit in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25: 403s.

    Google Scholar 

  • Eberhard DA, Giaccone G, Johnson BE . (2008). Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 26: 983–994.

    Article  Google Scholar 

  • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbot RS et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900–5909.

    Article  CAS  Google Scholar 

  • Eismann U, Oberschmidt O, Ehnert M, Fleeth J, Lüdtke F, Struck S et al. (2006). Thymidylate synthase gene expression in solid tumors predicts for response to pemetrexed in vitro. J Clin Oncol 24 (Suppl): 13058.

    Google Scholar 

  • Engelman JA, Jänne PA . (2008). Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14: 2895–2899.

    Article  Google Scholar 

  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043.

    Article  CAS  Google Scholar 

  • Gandara DR, Kawaguchi T, Crowley JJ, Moon J, Kawahara M, Teramukai S et al. (2007). Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): a model for testing population-related pharmacogenomics. J Clin Oncol 25 (Suppl): abstract 7500.

  • Gazdar AF . (2009). Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 (Suppl 1): S24–S31.

    Article  CAS  Google Scholar 

  • Granville CA, Dennis PA . (2005). An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32: 169–176.

    Article  CAS  Google Scholar 

  • Guney N, Soydinc HO, Derin D, Tas F, Camlica H, Duranyildiz D et al. (2008). Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer. Med Oncol 25: 194–200.

    Article  CAS  Google Scholar 

  • Han SE, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS et al. (2005). Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493–2501.

    Article  CAS  Google Scholar 

  • Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Tamaki Y, Monden M et al. (2002). Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int J Cancer 101: 46–51.

    Article  CAS  Google Scholar 

  • Hirsch FR, Varella-Garcia M, Bunn Jr PA, Franklin WA, Dziadziuszko R, Thatcher N et al. (2006). Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24: 5034–5042.

    Article  CAS  Google Scholar 

  • Hirsch FR, Varella-Garcia M, Cappuzzo F . (2009). Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28 (Suppl 1): S32–S37.

    Article  CAS  Google Scholar 

  • Hirsch J, Hansen KC, Burlingame AL, Matthay MA . (2004). Proteomics: current techniques and potential applications to lung disease. Am J Physiol Lung Cell Mol Physiol 287: L1–L23.

    Article  CAS  Google Scholar 

  • Huang CL, Yokomise H, Fukushima M, Kinoshita M . (2006). Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol 2: 289–299.

    Article  CAS  Google Scholar 

  • Huncharek M, Muscat J, Geschwind JF . (1999). K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 20: 1507–1510.

    Article  CAS  Google Scholar 

  • Kikuchi T, Carbone DP . (2007). Proteomics analysis in lung cancer: challenges and opportunities. Respirology 12: 22–28.

    Article  Google Scholar 

  • Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGFR receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665–7670.

    Article  CAS  Google Scholar 

  • Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al. (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702–4711.

    Article  CAS  Google Scholar 

  • Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF et al. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992–3995.

    Article  CAS  Google Scholar 

  • Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M et al. (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286–2291.

    CAS  PubMed  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.

    Article  CAS  Google Scholar 

  • Maheswaran S, Sequist LV, Nagrath S, Ulkus L . (2008). Detection of mutations in EGFR in circulating lung cancer cells. N Engl J Med 359: 1–12.

    Article  Google Scholar 

  • Marchetti A, Feliciomi L, Buttitta F . (2006). Assessing EGFR mutations. N Engl J Med 354: 526–528.

    Article  CAS  Google Scholar 

  • Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S et al. (2005). Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513–2520.

    Article  CAS  Google Scholar 

  • Mok T, Wu Y-L, Thongprasert S, Yang C-H, Chu D, Saijo N et al. (2008). Phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 19 (Suppl 8): viii1–viii4.

    Google Scholar 

  • Monzó M, Rosell R, Sánchez JJ, Lee JS, O’Brate A, González-Larriba JL et al. (1999). Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17: 1786–1793.

    Article  Google Scholar 

  • National Comprehensive Cancer Network (NCCN) (2008). Clinical practice guidelines. Non-small cell lung cancer v.2.2008. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed November 5, 2008.

  • Okano T, Kondo T, Nishimura T, Nishimura T, Takano T, Ohe Y et al. (2007). Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res 13: 799–805.

    Article  CAS  Google Scholar 

  • Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG . (2008). Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 44: 946–953.

    Article  CAS  Google Scholar 

  • Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib and erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.

    Article  Google Scholar 

  • Patterson SD . (2003). Data analysis—the Achilles heel of proteomics. Nat Biotechnol 21: 221–222.

    Article  CAS  Google Scholar 

  • Pitterle DM, Kim YC, Jolicoeur EM, Cao Y, O’Briant KC, Bepler G . (1999). Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). Mamm Genome 10: 916–922.

    Article  CAS  Google Scholar 

  • Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J et al. (2006). A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355: 570–580.

    Article  CAS  Google Scholar 

  • Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M et al. (2008). Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol 3: 117–124.

    Article  Google Scholar 

  • Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C et al. (2004). Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10: 1318–1325.

    Article  CAS  Google Scholar 

  • Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S et al. (2003). Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548–3553.

    Article  CAS  Google Scholar 

  • Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA et al. (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26: 2442–2449.

    Article  CAS  Google Scholar 

  • Sharma SV, Bell DW, Settleman J, Haber DA . (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169–181.

    Article  CAS  Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132.

    Article  CAS  Google Scholar 

  • Shepherd FA, Tsao MS . (2006). Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 24: 1219–1220.

    Article  Google Scholar 

  • Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C et al. (2007). Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 25: 2741–2746.

    Article  CAS  Google Scholar 

  • Simon GR, Sharma S, Cantor A, Smith P, Bepler G . (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127: 978–983.

    Article  Google Scholar 

  • Solan MJ, Werner-Wasik M . (2003). Prognostic factors in non-small cell lung cancer. Semin Surg Oncol 21: 64–73.

    Article  Google Scholar 

  • Solomon BJ, Roder H, Robert R, Taguchi F, Brahmer J, Joan SH et al. (2007). Validation of proteomic classifier for clinical benefit from erlotinib as first line treatment for advanced non-small cell lung cancer (ECOG 3505). J Clin Oncol 25 (Suppl): abstract 7508.

  • Stinchcombe TE, Socinski MA . (2008). Considerations for second-line therapy of non-small cell lung cancer. Oncologist 13 (Suppl 1): 28–36.

    Article  CAS  Google Scholar 

  • Takano T, Ohe Y, Sakamotto H, Tsuta K, Matsuno Y, Tateishi U et al. (2005). Epidermal growth factor receptor gene mutations and increased copy number predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829–6837.

    Article  CAS  Google Scholar 

  • Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS et al. (2004). BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13: 2443–2449.

    Article  CAS  Google Scholar 

  • Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J et al. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527–1537.

    Article  CAS  Google Scholar 

  • Tsao MS, Zhu C, Ding K, Strumpf D, Pintilie M, Meyerson M et al. (2008). A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. J Clin Oncol 26 (Suppl): abstract 7510.

    Article  Google Scholar 

  • Van Cutsem E, Lang I, D’haens G, Moiseyenko V, Zaluski J, Folprecht G et al. (2008). KRAS treated and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26 (Suppl): abstract 2.

  • Webster J, Oxley D . (2005). Peptide mass fingerprinting: protein identification using MALDI-TOF mass spectrometry. Methods Mol Biol 310: 227–240.

    Article  CAS  Google Scholar 

  • Wong KK . (2007). HKI-272 in non-small cell lung cancer. Clin Cancer Res 13 (15 Part 2): S4593–S4596.

    Article  Google Scholar 

  • Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC et al. (2003). Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362: 433–439.

    Article  CAS  Google Scholar 

  • Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Meyerson M et al. (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070–2075.

    Article  CAS  Google Scholar 

  • Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N et al. (2008). Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 4268–4275.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

I thank Johnathan C Maher, PhD of BlueSpark Healthcare Communications for medical and editorial assistance with this article. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals Inc.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

    R Pérez-Soler

Authors
  1. R Pérez-Soler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Pérez-Soler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pérez-Soler, R. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene 28 (Suppl 1), S38–S45 (2009). https://doi.org/10.1038/onc.2009.200

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2009.200

Keywords

This article is cited by

Search

Advanced search

Quick links